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In systemic lupus erythematosus (SLE) clinical manifesta-
tions, autoantibody production, and immunogenetics are 
inter-related. The ability to study parts of the autoimmune 
response may allow a more detailed understanding of 
these relationships. We undertook this study to determine 
whether the fine specificity of the autoimmune response to 
60-kD Ro(SS-A) was related to the presence of other autoan-
tibodies. We screened 74 patients with SLE for antibodies to 
the carboxyl 13-kD terminal of 60-kD Ro(SS-A) (13 kD). 
Twenty-five sera had such antibodies. This reactivity was 
distinguished by the presence of not only anti-Ro(SS-A) but 
also other antibodies. All nine sera with Ro(SS-A) and 
A nti_RO(SS_A) autoantibody precipitins are commonly fqund in the serum of patients with systemic lupus erythematosus (SLE), subacute cutaneous lupus ery-thematosus (SCLE) and Sjogren's syndrome as well as in the sera of mothers whose infants have congenital 
lupus [1]. The presence of anti-Ro(SS-A) is associated with several 
clinical features of SLE and Sjogren's syndrome including renal 
disease, lymphopenia, hypergammaglobulinemia, and the subacute 
cutaneous rash. Anti-Ro(SS-A) and anti-La(SS-B) together are asso-
ciated with an absence of renal disease in SLE and strongly asso-
ciated with congenital cutaneous lupus and complete congenital 
heart block [1-3] . Powerful genetic effects of alleles at HLA-DQ 
and for the T-cell receptor are associated with the production of 
anti-Ro(SS-A) [4 - 6]. 
The Ro(SS-A) ribonucleoprotein is operationally defined by its 
precipitin reaction with prototype sera and its association with the 
h Y RNAs. The Ro(SS-A) antigen is composed of at least a 60-kD 
peptide and anyone of the four h Y RN As [7] . The anti-Ro(SS-A) 
reactivity of sera is largely directed against the protein moiety [8] . 
Several other Ro(SS-A) peptides of 52, 54, and 46 kD have been 
recently described, though their relationship to the immune re-
sponse and to the hY RNAs is less understood [3,9]. 
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La(SS-B) Ouchterlony immunodiffusion precipitins bound 
13-kD (p = 0.01), whereas 10 of 11 sera with both anti-
Ro(SS-A) and anti-La(SS-B) as determined by immunosor-
bent assay bound 13-kD (p = 0.002) . Inhibition studies dem-
onstrated that antibodies binding the 13-kD fragment bound 
the 60-kD Ro(SS-A) protein but did not bind the La(SS-B) 
protein. Thus, anti-La(SS-B) was found in those sera that 
bound epitopes within the 13-kD carboxyl terminal of 60-
kD Ro(SS-A). These data suggest a structural basis by which 
anti-Ro(SS-A) and anti-La(SS-B) are coupled in SLE. ] Invest 
Dermato1 100:412-416,1993 
Only a few details of the fine specificity of the anti-Ro(SS-A) 
response are known. Reichlin and colleagues have determined that 
some human sera with anti-Ro(SS-A) only react with human 
Ro(SS-A) and not with Ro(SS-A) purified from other species. All of 
the human sera with anti-Ro(SS-A) analyzed to date preferentially 
bind with the human form ofRo(SS-A) [10] . Nonetheless, the per-
centage of anti-Ro(SS-A) binding only human Ro(SS-A) varies with 
the presence of other SLE-associated antibodies in the serum. For 
example, in sera with anti-Ro(SS-A) precipitins alone the anti-
Ro(SS-A) is directed preferentially towards human Ro(SS-A) when 
compared to those sera with both anti-Ro(SS-A) and anti-La(SS-B) 
or those with both anti-Ro(SS-A) and anti-Ul RNP [11]. Another 
study has shown that some sera with anti-Ro(SS-A) precipitins do 
not bind Ro(SS-A) in immunoblot [12] . 
Anti-Ro(SS-A) has also been shown to bind to other proteins. For 
instance, Mamula et al have shown that anti-Ro(SS-A) can bind 
immunoglobulin and therefore can be said to have rheumatoid fac-
tor activity [13]. In contrast, others have shown that anti-Ro(SS-A) 
does not bind the La(SS-B) antigen, nor does anti-La(SS-B) bind the 
Ro(SS-A) antigen [14]. Anti-La(SS-B), however, is found exclu-
sively, or almost exclusively, in combination with anti-Ro(SS-A) in 
the sera of patients with SLE, subacute cutaneous lupus erythemato-
sus, or Sjogren's syndrome [1-3]. We have recently addressed the 
fine specificity of the autoimmune response to the ribonucleopro-
tein Ro(SS-A) by production of large digestion fragments and short 
overlapping peptides [15] . A 13-kD V8 protease digestion fragment 
of 60-kD Ro(SS-A) has been localized to the carboxyl terminal of 
the molecule by amino acid sequencing. 
The present study was undertaken to determine if reactivity 
towards the carboxyl terminal fragment of the 60-kD Ro(SS-A) 
molecule found in a portion of those with anti-Ro(SS-A) was related 
to the presence of other antibody specificities. We found that, al-
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though antibodies to the 13-kD carboxyl terminal f~ag~~nt were 
present in each of the combl11atlons ,?f serologic specificIties, these 
antibodies were present 111 every patient With both antl-Ro(SS-A) 
and anti-La(SS-B) precipitins. In addition, when autoantibody speci-
ficities were determined by a sensitive enzyme-linked immunosor-
bent assay (ELISA) there remained a strong correlation between the 
presence of anti-La(SS-B) and binding to the 13-kD carboxyl termi-
nal fragment of the 60-kD Ro(SS-A) protein. 
MATERIALS AND METHODS 
Sera Sera were evaluated in double immunodiffusion for anti-
Ro(SS-A), anti-La(SS-B), anti-nRNP, and anti-Sm autoantibodies 
as described [13]. Normals conSisted of age- and sex-matched con-
trols without autoimmune disease. Patients were classified as to the 
presence or absence of renal disease according to established criteria 
[16]. 
Ro(SS-A) Purification and Digestion Bovine 60-kD R:0(SS-
A) was purified from spleen and digested as we l~ave prevIOusly 
described [15 ,17]. Human 60-kD Ro(SS-A) was punfied by an Iden-
tical method from human spleen and liver. Briefly, samples were 
evaporated to dryness and then solubilized with Staphylococcus aureus 
V8 protease (Type XVII-S, Sigma Chemicals, St. Louis, MO) at 
1: 15 (w: w) ratio to the Ro(SS-A) in 1 % sodium dodecY.l sulfate 
(SDS), and 50 gjml ofRN.Aase (Si&ma Chemicals, St. L,?U1S, M<?). 
Digestion was carned out 111 a shakl11g water bath at 37 C. Bov111e 
La(SS-B) was purified as previously described [15,17]. 
SDS Polyacrylamide Gel Electrophoresis and Immunoblot-
ting ofRo(SS-A) Digests Digests of purified ~O-kD Ro(SS-A) 
were subjected to polyacrylamide gel electrophoreSIS (12.5%) under 
reducing conditions as previously reported [15]. After transfer to 
nitrocellulose, immunoblots were performed using human autOim-
mune or normal sera at 1 : 100 dilution. Sera were classified accord-
ing to their abi lity to bind the 13-kD digestion fragment of60-kD 
Ro(SS-A) for purposes of this study. For inhibition experiments, 
sera was pre-incubated in 10 fLgjml of antigen, either purified 
Ro(SS-A) or La(SS-B), for 2 h at room temperature prior to immun-
obi otting. 
ELISA Anti-Ro(SS-A) and anti-La(SS-B) direct antigen solid-
phase assays were performed as presented previously. A positive 
result in either ELISA was taken to be a unit value of greater than 
twO standard deviations above normals and greater than 50% inhibi-
tion of binding by pre-incubation of sera with soluble antigen for 
2 h at room temperature [17] . In this assay, sera from patients with-
out SLE but with other rheumatic disease and sera from SLE patients 
without evidence of anti-Ro(SS-A) by other assays (including immu-
noprecipitatio~, Western immunoblot, and double immunodiffu-
sion) do not differ from normal controls (data not shown). 
RESULTS 
Bovine 60-kD Ro(SS-A) was purified to homogeneity as evidenced 
by Coomassie staining of the final product (Fig 1). In addition, we 
have sequenced 12 peptides from this material after complete claus-
tripain digestion and all 12 peptides are found in the human cDNA 
predicted amino acid sequence [18,19]. This effort has resulted 111 
determination of about 20% of the bovine 60-kD Ro(SS-A) se-
quence and the sequenced bovine pep tides are greater than 90% 
identical to the homologous human amino acid sequences (data not 
shown). The fact that all 12 peptides sequenced are apparently from 
60-kD Ro(SS-A) strongly argues that this preparation is highly 
pure. 
Digestion of purified bovine 60-kD Ro(SS-A) produced a num-
ber of fragments ranging in apparent molecular weight from 56,000 
to 13,000. The 13-kD fragment was localized to the carboxyl termi-
nal of the 60-kD Ro(SS-A) molecule by its amino terminal sequence 
and by its apparent molecular weight [15]. Of the twenty residues 
sequenced, 19 were identical to the predicted human sequence be-
ginning at amino acid residue 419. Immunoblots of the V8 protease 
digested Ro(SS-A) were performed on 74 sera from patients with 
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Figure 1. Coomassie Blue stained gel of purified bovine 60-kD Ro that 
demonstrates apparent homogeneity of the material. Lalle 1 demonstrates 
molecular weight markers; lalles 2 - 4 have 10, 5, and 1 Ilg of the purified 
Ro protein, respectively. 
SLE. Ea~h serum was classified according to its ability to bind the 
13-kD dlgest~on fragment l11.this assay. In addition, sera were parti-
tIOned accordl11g to the combl11atlon of precipitating autoantibodies 
pre~ent: Figure 2 shows representative blots from the subgroups, 
which I11cluded sera With precipitins binding a) Ro(SS-A) only and 
b) both Ro(SS-A) and La(SS-B). 
O.f the ~4 SLE sera tested, 25 bound the 13-kD fragment. Ability 
to bl11d thiS fragment of bovine Ro(SS-A) was associated with the 
presence of a Ro(SS-A) precipitin (p = 0.0001; see Table I). Of the 
two sera With antl-13-kD that did not have a coincident anti-
Ro(SS-A) precipitin, both bound Ro(SS-A) in other assays. One 
serum had 4,200,000 units of anti-Ro(SS-A) activity in ELISA 
whe~eas the other had only 4220 units. Negative normals had ap-
proximately 5000 ± 500 units in this assay. The second sera binds 
60-kD Ro(SS-A) 111 Western immunoblot with HeLa cell extract as 
the antigen source, as does the first sera, which bound in ELISA. 
~espite th~ relatio~ship of 13-kD binding and anti-Ro(SS-A) activ-
Ity, 12 patients With anti-Ro(SS-A) did not bind the 13 kD (see 
Table I). Thus, 13-kD antibodies were found in a subgroup of 
anti-Ro(SS-A) patients. 
Affinity-purified human 60-kD Ro(SS-A) was used for similar 
experiments using an identical digestion protocol with staphylococ-
cal V8 protease. Eleven sera that bound the bovine 13 kD fragment 
were used in immunoblots of the human material and all eleven sera 
bound a 13-kD fragment of digested human 60-kD Ro(SS-A~. 
Thus, these experiments demonstrated that bovine and human anti-
gen were equivalent for determination of anti-13-kD antibodies 
(data not shown). 
When binding to the 13-kD fragment ofRo(SS-A) was examined 
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Figure 2. SDS polyacrylamide gel electrophoresis and immunoblot of 
60-kD Ro/(SS-A) Digests. Partial Staph VB protease digests of bovine 
60-kD Ro I (SS-A) were subjected to SDS polyacrylamide gel electrophore-
sis, transferred to nitrocellulose, and then blotted with SLE patient sera 
having either anti-Roj(SS-A) alone (A ) or anti-Roj(SS-A) and anti-Laj 
(55-B) (B) . Position of undigested Ro/ (SS-A) is marked by the arrows at 60 
and position of the 13-kD carboxyl terminal fragment is marked by the 
arrows at 13. 
in relation to other autoantibody precipitins present, interesting 
differences emerged (see Table II). We found that all nine of the 
sera with Ro(SS-A) and La(SS-B) antibody precipitins bound the 
13-kD fragment (p = 0.01). Meanwhile, only 60% (11 of 17) of 
those with an anti-Ro(SS-A) precipitin alone bound the 13-kD 
fragment, and one third (three of eight) of the sera with nRNP 
precipitins or any other specificity in addition to anti-Ro(SS-A) 
bound the 13-kD fragment. 
When autoantibodies to Ro(SS-A) and La(SS-B) were deter-
mined by ELISA, there continued to be a strong association of anti-
La(SS-B) and anti -13 kD (see T able II) . Of 11 sera with both 
anti-Ro(SS-A) and anti-La(SS-B), 10 had antibody that bound the 
13-kD fragment of 60-kD Ro(SS-A) (p = 0.002) . Thus anti-La(SS-
B) was found almost exclusively in sera with anti-13 kD; however, 
the converse was not true. Anti-13 kD was found in half (11 of21) 
of the anti-Ro(SS-A) sera without anti-La(SS-B). Of eight sera with 
anti-Ro(SS-A) , and anti-nRNP or anti-Sm, but no anti-La(SS-B), 
only one had 13-kD antibodies. 
Given the strong association of anti-La with anti - 13 kD, we 
determined if antibodies binding the 13-kD fragment were anti-
Ro(SS-A) or anti-La(SS-B) specific. Six sera, three with anti-Ro(SS-
A) alone and three with anti-Ro(SS-A) and anti-La(SS-B), were used 
in soluble inhibition studies of 13-kD binding. The sera were incu-
bated in either purified 60-kD Ro(SS-A) or La(SS-B) at 10 J.lg/ml 
Table I. Relationship of Anti-13-kD Antibodies and Anti-
Ro(SS-A) Precipitating Antibodies" 
Anti-13kD 
+ 
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Table II. Relationship of Anti - 13-kD Antibodies to the 
Presence of Both Anti-Ro(SS-A) and Anti-La(SS-B) (Ro/ La) 













• Anti-Ro(SS-A) and anti-La(SS-B) were determined by either double immunodif-
fusion Or ELISA 
• P = 0.01 by Fisher's Exact Test. 
' p = 0.002 by Fisher's Exact Test. 
and then binding to the 13-kD fragment determined by immuno-
blot of V8 protease-digested 60-kD Ro(SS-A). The immunoblots 
demonstrated that anti - 13-kD antibodies were completely ab-
sorbed by incubation with 60-kD Ro(SS-A) although these antibod-
ies were not affected by incubation of the sera with La(SS-B) (Fig 3). 
Separate experiments were carried out using bovine or human 60-
kD Ro(SS-A) as the antigen and inhibitor. Similar results were 
obtained with both sources of 60-kD Ro(SS-A). 
Finally, because anti-La (SS-B) was associated with anti -13 kD 
and also associated with an absence of renal disease, we reasoned that 
perhaps the presence of anti - 13 kD would be related to renal dis-
ease. W e were able to evaluate clinical disease status in 53 patients. 
Of this number, 15 had kidney involvement as a manifestation of 
their SLE. When anti-13 kD and renal disease were examined, 
three of 17 patients with anti-13 kD had renal involvement com-
pared to 12 of 26 without anti - 13 kD (p = 0.25). This cohort of 
SLE patients confirmed previous observations [2] that anti-La(SS-B) 
is associated with an absence of renal involvement in that all eight 
patients with anti-La(SS-B) had sparing of their kidneys. These 
eight patients also had anti - 13 kD in their sera. When the anti-
La(SS-B) -positive patients were excluded from the evaluation, 
then three of nine anti-13-kD patients had renal disease, whereas 
11 of 25 without anti -13 kD had this manifestation of SLE (p > 
0.5). Thus, we conclude that anti- 13-kD antibodies are not a 
marker for the absence of renal disease. 
DISCUSSION 
The precise molecular structure of the Ro(SS-A) complex is un-
known. It is clear, however, that the 60-kD Ro(SS-A) protein is 
physically associated with at least one of the four hY RNAs. The 
52-kD Ro(SS-A) antigen may be associated with the 60-kD protein 
but not bound to the hY RNAs ([20], Itoh Y and Reichlin M, 
unpublished data). There is no evidence for or against a number of 
other peptides bound by anti-Ro(SS-A) sera being part of the 60-kD 
Ro(SS-A) complex. However, the hY RNAs have a 3' polyuridine 
tail that should provide a binding site for the La(SS-B) protein. In 
fact, evidence has been presented that La(SS-B) is a part of the 
60-kD Ro(SS-A)/ hY RNA complex [21]. A number of previous 
studies have shown that production of La(SS-B) autoantibodies is 
associated with the production of anti-Ro(SS-A) [1]- In fact, our 
group has not encountered a serum with an anti-La(SS-B) precipitin 
in which the concomitant presence of anti-Ro(SS-A) cannot be 
demonstrated [9]. The reverse is not the case, however, as many 
patients have anti-Ro(SS-A) without anti-La(SS-B). Thus anti-
La(SS-B) is found in a subset of those patients who have anti-Ro 
(SS-A). 
In this study we demonstrated that the production of anti-La(SS-
B) is related to the fine specificity of the autoimmune response to 
Ro(SS-A). Each of the nine patients in our study who produced 
precipitating levels of both anti-Ro(SS-A) and anti-La(SS-B) also 
produced antibodies towards a V8 protease 13-kD digestion frag-
ment of purified bovine 60-kD Ro(SS-A). Lupus sera with other 
combinations of precipitating antibodies, including anti-Ro(SS-A) 
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Figure 3. Inhibition of anti -13-kD aC.tivity by soluble antigen. A -F represent six p~tients with an.ti -13-kD antibo~y. The first latle in each panel is an 
SDS polyacrylanude gel electrophoresIs of VB protease-digested 60-kD Ro(SS-A) WIthout ~oluble mhlbltion by antigen. The middle latle in each panel 
demonstrates binding to the digested 60-kD Ro(SS-A) after incubation of the sera WIth pu~ed 60-kD Ro(SS-A) and the third lalle shows binding after 
incubation with affinity-purified La(SS-B). This series of experiments demonstrates that anti-13 kD antibody can be absorbed by incubation of sera with 
soluble Ro(SS-A) but not La(SS-B). 
alone, anti-Ro(SS-A) with anti-nRNP, and anti-Ro(SS-A) with an 
unidentified line, contained such antibodies in about 50% of cases. 
As expected, when anti-Ro(SS-A) and anti-La(SS-B) were deter-
mined by ELISA, a more sensitive test for such antibodies, t~1e num-
ber of sera with both these specificities increased. Sera With both 
anti-Ro(SS-A) and anti-La(SS-B) as determined ELISA were likely 
to contain antibodies directed towards the 13-kD fragment. Thus, 
the percent of sera with anti-Ro(SS-A) but not anti-La(SS-B) that 
bound the 13-kD fragment was reduced when ELISA reactivity was 
considered. 
Several previous studies have shown that anti-Ro(SS-A) antibod-
ies do not bind La(SS-B) [1,14] , although controversy remains con-
cerning this point [14]. More than one-half of anti - 13-kD positi~e 
sera do not contain anti-La (SS-B). This subset of anti-13-kD anti-
bodies thus do not bind the La(SS-B) protein. These sera suggest 
that the association of anti -13-kD and anti-La is not due to anti-
body cross-reactivity. Nonetheless, we have addressed this question 
experimentally. Pre-incubation of sera with 60-k~ Ro(SS-A) ~bro­
gates binding to the 13-kD fragment, demonstrat111g that antl-13 
kD antibodies are part of the anti-Ro(SS-A) response. 
The present study shows that sera with anti-Ro(SS-A) and ~n~i­
La(SS-B) bind the carboxyl 13 kD of 60-kD Ro(~S-A) p:ot~111 111 
Western immunoblot. It may be that a single epltope wltlun the 
13-kD digestion fra gment gives this carboxyl terminal fragment of 
Ro(SS-A) its association to anti-La(SS-B). This anti-La(SS-B) asso-
ciated epitope of 60-kD Ro(SS-A) is likely one conserved between 
human and bovine Ro(SS-A) considering the inhibition of binding 
by both human and bovine 60-kD Ro(SS-A). On the other hand, 
there may be a set of epitopes in this region of the 60-kD Ro(SS-A) 
molecule that are related to anti-La(SS-B). 
Given the previously demonstrated species specificity of anti-
Ro(SS-A) antibodies, we have used purified human 60-kD Ro(SS-
A) in these studies as well as bovine 60-kD Ro(SS-A) . The data 
demonstrate that sera that bind the 13-kD carboxyl terminus frag-
ment of bovine Ro(SS-A) also bind a 13-kd V8 protease fragment of 
purified human 60-kD Ro(SS-A) . Binding to the human 13-kD 
fragme nt can be inhibited by incubation of sera in soluble antigen. 
Thus, for the anti -13-kD specificity of anti-Ro, the human and 
bovine antigen are equivalent. 
The autoantibodies found in SLE have a variety of clinical associa-
tions. Potentially pertinent to this study is the protective association 
of the . combination of anti-Ro(SS-A) and anti-La(SS-B) against 
renal disease [2,3]. Given the strong association of anti - 13 kD and 
anti-La(SS-B), we have evaluated the relationship of renal disease to 
anti-13 kD and anti-La(SS-B). The presence of anti-13 kD does 
not predict the a bsence of renal disease in the entire group or in 
those patients Without antl-La(SS-B). Meanwhile, as has been previ-
ously noted, the presence of anti-La(SS-B) is highly predictive of no 
renal involvement by SLE. 
The factors influencing the production of autoantibodies have 
not been completely elucidated; however, several associations be-
tween the various autoantibodies and cl ass II antigens have been 
ma?e. The most dramatic of these is perhaps the association of 
antl-Ro(SS-A) With heterozygosity for DQ1/DQ2 in which a gene 
complementation effect is suggested between the DQ1 alpha and 
DQ2 beta gene products [4,6]. In addition, there have been several 
reports linking various combinations of autoantibodies to HLA 
markers. For example, anti-Ro(SS-A) without other specificities has 
been related to HLA DR2 and anti-Ro(SS-A) with anti-La(SS-B) 
has been related to H~A DR3 [1-3]. In addition, other immunoreg-
ulat?ry genes I?ay 111fluence the production of autoantibodies. 
Antl-Ro(SS-A) IS associated with two restriction fragment length 
polymorphis~s <;>f the T -cell receptor beta gene, for example [5] . 
The ~ne speCifiCity .of an autoimmune response may also be under 
ge~etlc control. In lIght of the strong association of anti-13 kD and 
antl-La(SS~B) antlbo~ies, it is possible to speculate that anti-La(SS-
B) pro~uctlon and tim element of the fine specificity of anti-Ro(SS-
A).are 111fluenced by a common genetic element. A common T-cell 
epltope between the 13-kD fragment and the La(SS-B) protein is 
another mecharusm by whIch these two autoantibody responses 
may ~e related. At present, T-cell epitopes have not been identified 
for eIther Ro(SS~A) or La(SS-B), nor have T-cell clones responsive 
to these autoantlgenic ribonucleoproteins been isolated. 
We l~ave ?emonstrated that within SLE sera with anti-Ro(SS-A) 
autoantibodIes, a subgroup binds the 13-kD carboxyl terminal of 
the 60-kD Ro(SS-A) protein in Western immunoblot. When the 
anti-Ro(SS-A) population is separated according to the presence of 
other SLE-assoclated antibodies then the anti-La(SS-B) antibodies 
are found nearly exclusively in sera with antibodies directed towards 
the 13-kD carboxyl terminus of 60-kD Ro(SS-A) . Thus, we have 
shown that the fine specificity of the anti-Ro(SS-A) response and 
the production of anti-La(SS-B) are related. 
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ANNOUNCEMENT 
The Fourth Dermatopathology and Oral Pathology Self Assessment Workshop will be held 
September 16,.17, 18, 1992 in Rome,Italy, with A.B. Ackerman (New York, USA), D.J. Santa 
Cruz (St. LOUIS, US~), and J.] . Sciubba (New Hyde Park, USA). 
The workshop ,:"i1l pro~lde an. In-depth review of difficult topics in dermatopathology: 
neoplasm With fo lhcular differentiation (A.B. Ackerman), eccrine tumors (D .]. Santa Cruz), 
and oral pathology (J.J. Sciubba). 
The pr.ogram will consist of a series of lectures and of a direct examination of slides. Micro-
scopes Will be pro.vlded for the participants. 
The co.urse fee IS US $200 for participation in all the activities of the course or US $ 100 for 
those desmng to attend the lectures only . 
. For furthe~ information please contact Guido Massi, M .D., Department of Pathology, Cath-
olic Umvemty, Largo F. Vito, 1,00168 Rome Italy. Tel (6) 3503481/33052345/5759733' 
fax (6) 3051343. ' 
